Submitted by dcc on Wed, 2019-04-17 11:12 Study Title: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin LymphomaCIRB: Adult CIRB - Late Phase EmphasisLead Group: ECOG-ACRINStatus: ActiveReview Status: Available to Open
